US-based clinical-stage medical device manufacturer Vivos Inc. is preparing to open two new production facilities across domestic and international locations, according to a GlobeNewswire press release.

The company, traded on OTCQB under the ticker RDGL, has identified single-site dependency as a risk factor in previous corporate filings and has spent two years assessing alternative production arrangements.

Its strategic target is to have one domestic facility, in which Vivos will serve as manufacturer of record, and one international facility both operational within 2026. Production with its existing contract manufacturer in Texas will continue through the second quarter of 2026.

For its domestic site, Vivos has signed a contract for production space at the Applied Process Engineering Laboratory in Richland, Washington. Manufacturing equipment has been ordered, installation is underway and licensing applications have been submitted.

The facility is intended to serve as the foundation for the company's automated production development, supporting higher volumes, improved efficiency and long-term capacity expansion. The site will also accommodate production of the company's Peltier and Duncan Chillers.

In parallel, Vivos is in discussions with radiopharmaceutical contract manufacturers in India regarding an international production site, with one facility anticipated to be operational by the end of 2026. An international footprint is expected to reduce shipping costs and logistical complexity while broadening access to global markets.

Both facilities will produce Y-90 phosphate particles combined with sterile hydrogel to manufacture individual patient doses for RadioGel, used in human oncology, and IsoPet, which is commercially available for veterinary oncology applications at certified clinics in the United States.

Get the full details on Vivos Inc.'s manufacturing expansion strategy in the complete press release.